For the year ending 2025-12-31, DNLI had $31,897K increase in cash & cash equivalents over the period. -$422,102K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -512,540 |
| Depreciation and amortization | 11,183 |
| Stock-based compensation expense | 99,633 |
| Net accretion of discounts on marketable securities | 10,253 |
| Non-cash adjustment to operating lease expense | 4,450 |
| Right-of-use asset amortization for finance lease | 3,629 |
| Non-cash gain from divestiture of small molecule programs | 0 |
| Other non-cash items | -49 |
| Prepaid expenses and other current assets | 540 |
| Other non-current assets | -772 |
| Accounts payable | -7,520 |
| Accruals and other current liabilities | 465 |
| Related party contract liability | 0 |
| Deferred research and development funding liability | 6,972 |
| Other non-currentliabilities | 0 |
| Net cash used in operating activities | -412,600 |
| Maturities of marketable securities | 706,046 |
| Purchases of marketable securities | 441,263 |
| Purchases of property and equipment | 9,502 |
| Net cash provided by (used in) investing activities | 255,281 |
| Proceeds from issuance / public offering of common stock and pre-funded warrants, net of issuance costs of-Private Placement | 0 |
| Proceeds from issuance / public offering of common stock and pre-funded warrants, net of issuance costs of-Public Offering | 189,249 |
| Proceeds from exercise of awards under equity incentive plans | 8,459 |
| Payments for finance lease right-of-use asset | 8,168 |
| Issuance costs related to the royalty financing | 324 |
| Net cash provided by financing activities | 189,216 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 31,897 |
| Cash, cash equivalents and restricted cash at beginning of year | 176,535 |
| Cash, cash equivalents and restricted cash at end of year | 208,432 |
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)